{"id":251635,"date":"2023-10-25T00:00:00","date_gmt":"2023-10-25T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0021-biopharma-obstructive-sleep-apnea-epidemiology-mature\/"},"modified":"2026-03-31T10:31:56","modified_gmt":"2026-03-31T10:31:56","slug":"epidim0021-biopharma-obstructive-sleep-apnea-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0021-biopharma-obstructive-sleep-apnea-epidemiology-mature-markets\/","title":{"rendered":"Obstructive Sleep Apnea &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of obstructive sleep apnea (<abbr title=\"obstructive sleep apnea\">OSA<\/abbr>) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of <abbr title=\"obstructive sleep apnea\">OSA<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"obstructive sleep apnea\">OSA<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people living with <abbr title=\"obstructive sleep apnea\">OSA<\/abbr>?<\/li>\n<li>How will demographic trends such as population aging and improving life expectancy affect the epidemiology of <abbr title=\"obstructive sleep apnea\">OSA<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <span class=\"abbreviation-guard\">MS <\/span>Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as a part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 12 <abbr title=\"obstructive sleep apnea\">OSA<\/abbr> patient populations as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Total prevalent cases.<\/li>\n<li>Total prevalent cases by severity.\n<ul class=\"round-bullets\">\n<li>Total prevalent cases of mild <abbr title=\"obstructive sleep apnea\">OSA<\/abbr>.<\/li>\n<li>Total prevalent cases of moderate <abbr title=\"obstructive sleep apnea\">OSA<\/abbr>.<\/li>\n<li>Total prevalent cases of severe <abbr title=\"obstructive sleep apnea\">OSA<\/abbr>.<\/li>\n<\/ul>\n<\/li>\n<li>Total prevalent cases by comorbidity.\n<ul class=\"round-bullets\">\n<li>Total prevalent cases with comorbid stroke.<\/li>\n<li>Total prevalent cases with chronic heart failure.<\/li>\n<li>Total prevalent cases with comorbid atrial fibrillation.<\/li>\n<li>Total prevalent cases with comorbid asthma.<\/li>\n<li>Total prevalent cases with comorbid obesity.<\/li>\n<li>Total prevalent cases with no comorbid obesity.<\/li>\n<\/ul>\n<\/li>\n<li>Diagnosed prevalent cases.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251635","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-obstructive-sleep-apnea","biopharma-therapy-areas-respiratory","biopharma-product-epidemiology","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251635","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251635\/revisions"}],"predecessor-version":[{"id":281317,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251635\/revisions\/281317"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251635"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}